{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gruber A"],"funding":["F. Hoffmann-La Roche"],"pagination":["763-771"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5854746"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["81(4)"],"pubmed_abstract":["PURPOSE:In this study, a therapeutic drug monitoring (TDM) of erlotinib in pancreatic cancer patients was performed over 50 weeks to reveal possible alterations in erlotinib plasma concentrations. Additionally, a physiologically based pharmacokinetic (PBPK) model was created to assess such variations in silico. METHODS:Patients with advanced pancreatic cancer received a chemotherapeutic combination of 100 mg erlotinib q.d., 500-900 mg capecitabine b.d. and 5 mg/kg bevacizumab q.2wks. Samples were analyzed by HPLC and the results were compared to a PBPK model, built with the software GastroPlus™ and based on calculated and literature data. RESULTS:The erlotinib plasma concentrations did not show any accumulation, but displayed a high inter-patient variability over the whole investigated per"],"journal":["Cancer chemotherapy and pharmacology"],"pubmed_title":["Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model."],"pmcid":["PMC5854746"],"funding_grant_id":["FA555004"],"pubmed_authors":["Gruber A","Kirchbaumer Baroian N","Sahmanovic Hrgovcic A","Czejka M","Dittrich C","Kitzmueller M","Buchner P"],"additional_accession":[]},"is_claimable":false,"name":"Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.","description":"PURPOSE:In this study, a therapeutic drug monitoring (TDM) of erlotinib in pancreatic cancer patients was performed over 50 weeks to reveal possible alterations in erlotinib plasma concentrations. Additionally, a physiologically based pharmacokinetic (PBPK) model was created to assess such variations in silico. METHODS:Patients with advanced pancreatic cancer received a chemotherapeutic combination of 100 mg erlotinib q.d., 500-900 mg capecitabine b.d. and 5 mg/kg bevacizumab q.2wks. Samples were analyzed by HPLC and the results were compared to a PBPK model, built with the software GastroPlus™ and based on calculated and literature data. RESULTS:The erlotinib plasma concentrations did not show any accumulation, but displayed a high inter-patient variability over the whole investigated per","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Apr","modification":"2025-04-18T11:49:54.117Z","creation":"2019-06-06T19:08:35Z"},"accession":"S-EPMC5854746","cross_references":{"pubmed":["29453635"],"doi":["10.1007/s00280-018-3545-4"]}}